Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss

summarizeResumen

The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.

check_boxEventos clave

• Going Concern Warning Issued

  Management disclosed a material uncertainty regarding the company's ability to continue as a going concern, citing historical operating losses and negative cash flows.

• Significant Revenue Decline

  Revenue for the nine months ended September 30, 2025, plummeted 85% year-over-year to $500,433, primarily due to the expiration of a major customer agreement.

• Shift to Comprehensive Loss

  The company reported a comprehensive loss of $916,042 for the nine-month period, a significant reversal from income in the prior year.

• Cash Flow Deterioration

  Net cash used in operating activities resulted in a $600,111 decrease in cash and cash equivalents for the nine-month period.

auto_awesomeAnalisis

The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.